A prospective, randomized, phase II study of preoperative plus postoperative imatinib mesylate (Gleevec, formerly STI-571) in patients with primary, recurrent, or metastatic resectable, Kit-expressing, gastrointestinal stromal tumor (GIST).
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2011
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 04 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Apr 2011 Planned end date changed from 1 Jul 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 18 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.